WEST

Freeform Search

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Image**

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences

Search History

Today's Date: 5/1/2001

DB Name	Query	Hit Count	Set Name
USPT,PGPB,JPAB,EPAB,DWPI	l4 same recombinant same human	5	L11
USPT,PGPB,JPAB,EPAB,DWPI	l4 same "fusion"	5	L10
USPT,PGPB,JPAB,EPAB,DWPI	l4 same "epo"	5	L9
USPT,PGPB,JPAB,EPAB,DWPI	l4 same "sf"	4	L8
USPT,PGPB,JPAB,EPAB,DWPI	l4 same "gm-csf"	9	L7
USPT,PGPB,JPAB,EPAB,DWPI	l4 same "g-csf"	6	L6
USPT,PGPB,JPAB,EPAB,DWPI	l4 same (medium or media)	9	L5
USPT,PGPB,JPAB,EPAB,DWPI	"flt3-l$"	16	L4
USPT,PGPB,JPAB,EPAB,DWPI	l1 or l2	71	L3
USPT,PGPB,JPAB,EPAB,DWPI	beckman-m$.in.	26	L2
USPT,PGPB,JPAB,EPAB,DWPI	lyman-s$.in.	45	L1

```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:27 ON 01 MAY 2001)

     FILE 'MEDLINE' ENTERED AT 10:29:31 ON 01 MAY 2001
L1           417 S FLT3-L OR FLT3-LIGAND/AB,BI
L2            74 S L1 AND G-CSF/AB,BI
L3            18 S FLT3/FLK2 LIGAND/AB,BI

     FILE 'STNGUIDE' ENTERED AT 10:32:42 ON 01 MAY 2001

     FILE 'MEDLINE' ENTERED AT 10:34:44 ON 01 MAY 2001
L4           423 S L1 OR L3
L5            74 S L2 AND L4
L6            99 S L4 AND GM-CSF/AB,BI
L7            17 S L4 AND SF/AB,BI
L8            30 S L4 AND EPO/AB,BI
L9            24 S L4 AND FUSION/AB,BI

     FILE 'MEDLINE, EMBASE, BIOSIS, INPADOC, CAPLUS' ENTERED AT 10:39:12 ON
01
     MAY 2001
                E LYMAN S/AU
L10          409 S E3 OR E6
L11          170 S L10 AND L4
L12         1799 S L4
                E LYMAN STEWART/AU
L13          236 S E1-E5
L14           98 S L13 AND L4
L15           60 DUP REM L14 (38 DUPLICATES REMOVED)
                E BECKMAN M/AU
L16           73 S E3 OR E12
                E BECKMAN M PATRICIA/AU
L17            5 S E3
L18           78 S L16 OR L17
L19            1 S L18 AND L4
L20          383 S L6
L21          177 DUP REM L20 (206 DUPLICATES REMOVED)
L22           59 S L7
L23           23 DUP REM L22 (36 DUPLICATES REMOVED)
L24          104 S L8
L25           38 DUP REM L24 (66 DUPLICATES REMOVED)
L26           82 S L9
L27           49 DUP REM L26 (33 DUPLICATES REMOVED)
```

WEST

Generate Collection

L11: Entry 1 of 5 File: USPT Feb 20, 2001

DOCUMENT-IDENTIFIER: US 6190655 B1
TITLE: Methods of using Flt-3 ligand for exogenous gene transfer

BSPR:
Transformed yeast host cells are preferably employed to express flt3-L as a secreted polypeptide in order to simplify purification. Secreted recombinant polypeptide from a yeast host cell fermentation can be purified by methods analogous to those disclosed by Urdal et al. (J. Chromatog. 296:171, 1984). Urdal et al. describe two sequential, reversed-phase HPLC steps for purification of recombinant human IL-2 on a preparative HPLC column.

DEPR:
Prior to cell collection, it may be desirable to mobilize or increase the numbers of circulating PBPC and PSC. Mobilization can improve PBPC and PSC collection, and is achievable through the intravenous administration of flt3-L to the patients prior to collection of such cells. Other growth factors such as CSF-1, GM-CSF, SF, G-CSF, EPO, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF/IL-3 fusion proteins, LIF, FGF and combinations thereof, can be likewise administered in sequence, or in concurrent combination with flt3-L. Mobilized or non-mobilized PBPC and PSC are collected using apheresis procedures known in the art. See, for example, Bishop et al., Blood, vol. 83, No. 2, pp. 610-616 (1994). Briefly, PBPC and PSC are collected using conventional devices, for example, a Haemonetics Model V50 apheresis device (Haemonetics, Braintree, Mass.). Four-hour collections are performed typically no more than five times weekly until approximately 6.5.times.10.sup.8 mononuclear cells (MNC)/kg patient are collected. Aliquots of collected PBPC and PSC are assayed for granulocyte-macrophage colony-forming unit (CFU-GM) content by diluting approximately 1:6 with Hank's balanced salt solution without calcium or magnesium (HBSS) and layering over lymphocyte separation medium (Organon Teknika, Durham, N.C.). Following centrifugation, MNC at the interface are collected, washed and resuspended in HBSS. One milliliter aliquots containing approximately 300,000 MNC, modified McCoy's 5A medium, 0.3% agar, 200 U/mL recombinant human GM-CSF, 200 u/mL recombinant human IL-3, and 200 u/mL recombinant human G-CSF are cultured at 37 C in 5% CO.sub.2 in fully humidified air for 14 days. Optionally, flt3-L or GM-CSF/IL-3 fusion molecules (PIXY 321) may be added to the cultures. These cultures are stained with Wright's stain, and CFU-GM colonies are scored using a dissecting microscope (Ward et al., Exp.

are scored using a dissecting microscope (Ward et al., Exp. Hematol., 16:358 (1988). Alternatively, CFU-GM colonies can be assayed using the CD34/CD33 flow cytometry method of Siena et al., Blood, Vol. 77, No. 2, pp 400-409 (1991), or any other method known in the art.